Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab Before and After Surgery in Recurrent High-grade Glioma
NCT07788677Phase 1Not yet recruiting
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tarlatamab in glioma, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoints: Number of Participants Completing the DLT Evaluation Period and Undergoing Planned Surgery Without a DLT, Number of Participants With Treatment-Emergent Adverse Events and 3 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
tarlatamab
03
Conditions
glioma
Beyond the preview
Go deeper on NCT07788677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07788677.